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Photo-induced uncaging of a speciﬁc Re(I)
organometallic complex in living cells†
Anna Leonidova,‡a Vanessa Pierroz,‡ab Riccardo Rubbiani,‡a Yanjun Lan,a
Anita G. Schmitz,a Andres Kaech,c Roland K. O. Sigel,a Stefano Ferrarib
and Gilles Gasser*a
In the last decades, a large number of organometallic complexes have shown promising anti-proliferative
activity towards diﬀerent cancer cell lines. However, these compounds generally had low cellular uptake
and low selectivity towards cancer cells over healthy cells. The use of external triggers (e.g. light, ultra-
sound, temperature, etc.) to modify the cytotoxic eﬀect of a prodrug and the coupling of a targeting
vector (e.g. peptides, antibodies, etc.) to a drug were found to be very successful techniques to tackle
these drawbacks. Here, we envisioned combining these two methods, namely an external trigger (i.e.
light activation) and a targeting vector, in an organometallic compound. More speciﬁcally, a Re(I)
tricarbonyl N,N-bis(quinolinoyl) complex (Re-NH2) was derivatised with a photo-labile protecting group
(PLPG) to cage Re-NH2 by formation of Re-PLPG. For organelle/cellular speciﬁcity, Re-PLPG was then
further coupled to a nuclear localization sequence (NLS) or a bombesin peptide derivative to give Re-
PLPG-NLS or Re-PLPG-Bombesin, respectively. Photolysis experiments in PBS buﬀer (pH 7.4)
demonstrated that Re-NH2 was completely photo-released from Re-PLPG-NLS and Re-PLPG-Bombesin
using a very low irradiation dose (1.2 J cm2). To the best of our knowledge, these are the ﬁrst two
examples of the selective photo-release of an intact organometallic compound from a bioconjugate. Of
high interest, both derivatives showed toxicity comparable to that of cisplatin towards cervical cancer
cells (HeLa) upon light irradiation, although the phototoxic index (PTI) varied greatly with the targeting
peptide. The cell death mechanism of Re-PLPG-NLS was explored using diﬀerent techniques, including
ﬂuorescence microscopy, ICP-MS, gel electrophoresis, ﬂow cytometry and transmission electron
microscopy (TEM). It could be demonstrated that HeLa cells treated with Re-PLPG-NLS in the dark and
upon irradiation showed severe cell stress (nucleolar segregation, pyknosis and vacuolation). The data
obtained from an Annexin V/propidium iodide (PI) assay indicated that, after an early apoptotic stage, the
onset induced by Re-PLPG-NLS led to cell death, with features ascribable to late apoptosis and necrosis,
which were more marked for the treatment involving irradiation.
Introduction
Photodynamic therapy (PDT) is a medical technique that
allows the destruction of target cells by irradiation of a pho-
tosensitiser (PS) with light. Oﬀering important advantages,
such as temporal and spatial control, PDT is currently used to
treat certain cancers that are readily accessible with lamps or
optic bers (e.g. some types of head and neck, skin, bladder,
lung and oesophagus cancers).2 Other applications of PDT –
treatment of multi-drug resistant bacterial infections in
particular – are also being actively explored.3–8 However, PDT
suﬀers from a general drawback, namely its reliance on an
oxygen-dependent mechanism. In fact, the two main PDT
modes of action (type I which involves reactive oxygen species
(ROS) production, and type II in which the damage is directly
produced by 1O2) rely on the conversion of oxygen from its
triplet ground state to its singlet excited state by a PS. This can
be problematic since tumours, in their inner central part in
particular, are oen hypoxic.9,10 Hence, it would be extremely
interesting to develop a light-mediated strategy that does not
rely on the presence of oxygen. In this sense, singlet oxygen
generation is not the only eﬀect that light can induce. Chem-
ical bonds can also be rearranged and/or cleaved upon light
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irradiation. Indeed, the activity of a compound may be modi-
ed by caging some of its functional groups with a photo-
removable moiety. The release of the original compound can
then be controlled by light irradiation. Such light-activated
molecules have proven themselves useful tools in biological/
chemical biology/medicinal chemistry studies, such as in the
analysis of neurological and enzymatic processes, gene
expression, cell signalling and many others.11,12 Several drugs
and drug candidates have also been photo-caged and eﬃ-
ciently released upon light irradiation.13–19 Among them are
aspirin,13 ibuprofen,13 ketoprofen,13 carbonic anhydrase II
inhibitors,14 as well as a few anti-cancer agents such as ux-
oridine,15 paclitaxel,16 tegafur,17 doxorubicin,18 and a photo-
reactive DNA intercalator.19 Recently, this photo-caging strategy
has also been combined with singlet oxygen generation: an
anti-cancer drug candidate, combretastatin A-4, has been
coupled to a porphyrin photosensitiser via a cleavable singlet
oxygen linker.20 Surprisingly, although many studies reporting
the use of photo-caged organic molecules have been published,
examples of the specic release of intact (organo)metallic
compounds using light as a trigger are very scarce.21 Surely,
some complexes are known to undergo light-induced reactions
involving the metal centre itself. This property was used not
only to enhance their cytotoxicity,22–39 but also to design metal-
based photo-cages.40–44 As shown by Franz and co-workers
using a photo-labile o-nitrophenyl moiety, the release of a
labile metal complex45 or the release of metal ions46,47 could
also induce cytotoxicity. Of note, the photo-release of metal
ions alone to explore neurological response and cell signalling
is currently an intensively investigated research area.48–52
However, to the best of our knowledge, we were the rst to
report the photo-release of an intact cytotoxic substitutionally
inert Ru(II) complex upon light irradiation.21 While most drugs
on the market are organic molecules, the platinum(II)-based
drug cisplatin and its derivatives oxaliplatin and carboplatin
are playing a pivotal role in anti-cancer chemotherapy. In
addition to purely metal coordination complexes, a signicant
number of organometallic compounds have been reported to
be strongly toxic towards cancer cells in recent years.53–57
Among them, rhenium tricarbonyl complexes may not be the
most numerous, but are particularly attractive, as their iso-
structural 99mTc analogues permit the use of imaging to
observe the compound's behaviour in vivo. In this work, we are
building on the information gained during a previous study on
a Re(I) tricarbonyl bis(quinolinoyl) complex that showed a
strong PDT prole1 to achieve multi-modal activity. We
observed that synthetic modications of the alkyl chain of
these Re(I) complexes (see Scheme 1) strongly inuenced both
their dark and light-mediated cytotoxicities.1,58 Hence, photo-
caging and peptide conjugation of these compounds could
provide temporal and spatial control. Moreover, we envisaged
boosting the uptake of our derivative by malignant tissues via
conjugation of targeting peptides. Herein, we report the
synthesis and characterization of photo-activated targeted Re(I)
tricarbonyl N,N-bis(quinolinoyl) bioconjugates, as well as their
photo-products. Their bioactivity towards cervical (HeLa) and
prostate (PC-3) cancer cells, as well as towards normal lung
broblasts (MRC-5), upon light activation is described. The
possible modes of cytotoxic action are also explored in depth.
Results and discussion
Synthesis and characterization of the organometallic caged
bioconjugates
Re-NH259 was caged with an o-nitrophenyl-based photo-linker,
namely the Dmochowski photo-labile protecting group
(PLPG).60 This type of photo-linker has been systematically
studied and applied in numerous biochemical systems.12,61–64
Besides, it allows coupling of additional molecules – a property
we used to attach targeting peptides to our caged Re(I) deriva-
tive. More specically, the primary amino group of Re-NH2 was
rst reacted with PLPG via N-hydroxysuccinimide ester coupling
to give Re-PLPG (Scheme 1).60 For this purpose, the original
Dmochowski protocol was slightly modied. The phosphate
buﬀer was replaced by organic solvents to solubilise the
organometallic compounds, and a weak base was added to
catch the protons liberated during the reaction. Although the
presence of a base can induce maleimide ring opening,60 only a
small amount of by-product was observed. The formation of Re-
PLPG was conrmed by ESI-MS, which showed the expected
mass of [M]+ at m/z 943.2, as well as the isotopic pattern char-
acteristic of rhenium (Fig. S3 in the ESI†). In the 1H NMR
spectrum, a new peak corresponding to the amide proton of the
newly formed carbamate bond appeared at approximately 5.7
ppm. As expected, a shi of the signals of the protons in the
immediate vicinity of the carbamate was observed. In Re-PLPG,
the signals of the methyl group of the PLPG moiety and its
neighbouring tertiary carbon proton shied upeld compared
to PLPG. Slight (both upeld and downeld) changes
in chemical shis were also observed for the protons of
the organometallic part of Re-PLPG compared to Re-NH2
(Fig. S5–S7†).
The photo-caged complex Re-PLPG was then conjugated to
two diﬀerent targeting peptides via Michael addition of the
cysteine thiol of a peptide to the maleimide bond of the PLPG
(Scheme 1). Re-PLPG was attached to (1) a nucleus localization
signalling (NLS) peptide to target the compound to the nucleus
in close proximity to DNA and (2) a bombesin derivative65,66 to
improve the uptake of the compound by cancer cells over-
expressing the gastrin-releasing peptide receptor (GRPR). A
cysteine residue was added to each peptide to allow conjugation
to the PLPG maleimide. Aer preparative HPLC purication
and lyophilisation, light yellow solids of Re-PLPG-NLS and Re-
PLPG-Bombesin were obtained. The expected masses at m/z
415.7 [M + 3H]4+, 553.9 [M + 2H]3+ and 830.3 [M +H]2+ (Re-PLPG-
NLS) and at m/z 538.4 [M + 3H]4+, 717.4 [M + 2H]3+ and 1075.3
[M + H]2+ (Re-PLPG-Bombesin) were observed by ESI-MS
(Fig. S9–S16†). The purity of the bioconjugates was unambigu-
ously conrmed by LC-MS, in which two peaks in very close
proximity with the same mass pattern were observed, corre-
sponding to the two possible diastereomers formed during the
Michael addition. Such behaviour was previously reported for
biotin conjugated compounds photo-caged with a similar
PLPG.18,67 Two small extra m/z peaks were sometimes observed
This journal is © The Royal Society of Chemistry 2014 Chem. Sci., 2014, 5, 4044–4056 | 4045
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in the mass spectra during LC-MS. They could be assigned to
the photo-uncaged but not yet decarboxylatedmetal complex, as
well as to the fully uncaged complex. This uncaging process
clearly happens during the electrospray ionization process due
to the harsh ionization conditions used for LC-MS, since the
uncaged complex is eluted over a diﬀerent time frame (Fig. S12
and S16–S18 in the ESI†).
Photo-release of the organometallic complex
In order to verify the photo-uncaging eﬃciency of our system,
the photo-release of Re-NH2 from the two prepared bio-
conjugates, namely Re-PLPG-NLS and Re-PLPG-Bombesin, was
then investigated in phosphate buﬀer solution (PBS, pH 7.4). To
determine the light dose required to photo-release Re-NH2 from
Re-PLPG-NLS and Re-PLPG-Bombesin in cells, the two
compounds were irradiated using a Rayonet UV reactor (350
nm) that was later used in the cell culture experiments. Both Re-
PLPG-NLS and Re-PLPG-Bombesin completely photo-released
Re-NH2 using a very low irradiation dose of 1.2 J cm
2 – four
times lower than the dose used to completely photolyze the
caged Ru complex previously reported by our group.21 During
the irradiation, the composition of the solutions was monitored
by LC-MS. As shown in Fig. 1 for Re-PLPG-NLS, prior to irradi-
ation, only two peaks at 12.6–13.3 min, corresponding to the
two diastereomers, were present. As the caged complex was
irradiated, new peaks arose in the chromatograms. The rst
small peaks at 9.8–10 min were assigned to the by-products of
the UV decomposition of the PLPG (Fig. S17 and S19†) that have
been reported for o-nitrobenzyl photo-linkers.12 The released
Re-NH2 complex is detected at 14.5 min. In the case of Re-PLPG-
Bombesin, the order of peak appearance changes, as bombesin
is more lypophilic than NLS (Fig. S18†). The released Re-NH2 is
eluted rst, followed by o-nitrobenzyl moiety by-products, while
the remaining Re-PLPG-Bombesin peak is eluted last. Photol-
ysis quantum yields were then measured using a 355 nm laser
setup. As expected, the targeting peptide had no inuence, and
both Re-PLPG-NLS and Re-PLPG-Bombesin achieved a good
photolysis quantum yield of 10  2% (value obtained using
Scheme 1 Synthesis of bioconjugated organometallic photo-caged derivatives Re-PLPG-NLS and Re-PLPG-Bombesin. (i) TEA, acetonitrile; (ii)
H2O, MeOH.
Fig. 1 (a) Steady state photolysis of Re-PLPG-NLS irradiated in a UV
reactor (lampmax. output at 350 nm, 42Wm2, 30 C); (b) exponential
ﬁt of Re-PLPG-NLS and Re-PLPG-Bombesin photo-decomposition,
and of Re-NH2 release during photolysis.
4046 | Chem. Sci., 2014, 5, 4044–4056 This journal is © The Royal Society of Chemistry 2014
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azobenzene actinometry using the azobenzene quantum yield
of 0.15, Fig. S20 and S21†).68
(Photo-)toxicity
The cytotoxicity of the photo-caged bioconjugates Re-PLPG-NLS
and Re-PLPG-Bombesin, as well as of the Re-NH2 complex,
towards cancerous (HeLa) and non-cancerous (MRC-5) cells was
evaluated in the presence and the absence of light. Cisplatin
was used as a positive control (although it is not a PDT agent), in
order to compare the cytotoxicity of our compounds to that of a
successful metal-based drug. Re-PLPG-Bombesin was addi-
tionally tested on prostate cancer cells (PC-3), as the analogue of
bombesin used in this study has been optimised on this cell
line, which over-expresses GRPR.65,66 HeLa cells also over-
express receptors belonging to the bombesin receptor family,
namely the bombesin receptor subtype 3 (BSR-3), for which our
bombesin derivative should also have some aﬃnity.69 As shown
in Table 1, 48 h of incubation, photo-caging and peptide
conjugation strongly aﬀected both the dark and light toxicity of
the compounds. In general, the bioconjugates with NLS peptide
(Re-NLS and Re-PLPG-NLS) showed a marked increase in dark
cytotoxicity compared to Re-NH2 (up to 13-fold), while the
bombesin derivatives displayed only moderate toxicity towards
MRC-5 cells and remained inactive up to the highest concen-
tration used in this study (100 mM) towards HeLa and PC-3.
While the presence of the PLPG rendered Re-PLPG-NLS almost
2.5 times more toxic towards HeLa cells than Re-NLS, it did not
aﬀect the cytotoxicity of the bombesin derivative Re-PLPG-
Bombesin towards HeLa and PC-3, and actually attenuated (up
to 2-fold) the eﬀect of the compounds on the non-cancerous cell
line MRC-5.
The inuence of light on the activity of Re-PLPG-NLS and Re-
PLPG-Bombesin was studied by incubating cells with the
compounds for 4 h. This incubation time frame has been shown
to allow suﬃcient uptake of Re-NH2 for its phototoxic eﬀect to
be observed.1 Aer incubation, the medium was replaced with a
compound-free fresh medium, the cells were irradiated at
350 nm (UV reactor) with a low light dose of 2.58 J cm2, and the
viability of the cells was quantied 44 h later. Light irradiation
increased the toxicity of almost all tested compounds towards
HeLa, PC-3 and MRC-5. The UVA irradiation by itself did not
aﬀect cell viability (Fig. S22†). Interestingly, although light
signicantly increased the cytotoxicity of the Re-NH2 complex
towards HeLa (10-fold) and MRC-5 cells (2.5-fold), irradiated
PC-3 cells remained unaﬀected at a Re-NH2 concentration of up
to 100 mM. Derivatization of Re-NH2 with bombesin allowed
much more eﬃcient targeting of this particular cancer cell line
(5–7 phototoxic index (PTI)). In addition, the bombesin
conjugates Re-Bombesin and Re-PLPG-Bombesin showed good
light-induced increases in cytotoxicity towards the HeLa cell
line (10–20 fold). However, no signicant diﬀerence (within the
error range) in phototoxicity between Re-Bombesin and Re-
PLPG-Bombesin – i.e. no inuence of the PLPG – was observed.
These results suggest a predominant singlet oxygen-dependent
mode of cytotoxic action that, together with an acceptable PTI
towards cancer cell lines and moderate toxicity towards healthy
MRC-5 cells, makes these two bombesin derivatives interesting
for PDT applications. In fact, some commercially available PSs
have comparable PTIs (at a similar light dose of 1.5 J cm2), e.g.
Photofrin (PTI 3), Hypercin (PTI 27) and ALA-induced PPIX.70
Only Foscan and Fospeg achieve PTIs of 268 and 4695 respec-
tively.70 Compared with our previously reported caged Ru(II)
species that use a similar photo-caging moiety, Re-Bombesin
and Re-PLPG-Bombesin possess better phototoxicity character-
istics (higher PTI and higher light toxicity).21 However, in the
area of photoactive metal compounds acting via singlet oxygen
production or ligand lability, similar or higher (typically in the
100–200 range) PTIs with both UVA and visible light have
already been achieved,34,35,44,71–78 although oen with higher
light doses (up to 100 J cm2) and longer irradiation times.
Upon light irradiation, the NLS derivatives behaved quite
diﬀerently to the bombesin bioconjugates. Re-NLS and Re-
PLPG-NLS possess lower PTIs (2 or less), and show a more
pronounced diﬀerence between the PLPG-peptide conjugate
(Re-PLPG-NLS) and the peptide-only derivative (Re-NLS). In this
case, the presence of the PLPG confers a certain advantage. Re-
PLPG-NLS had a stronger (2-fold) anti-proliferative eﬀect on
malignant HeLa cells compared with Re-NLS. In addition, Re-
PLPG-NLS aﬀected non-cancerous MRC-5 cells less, compared
with Re-NLS. To explore the origin of these diﬀerences, the
eﬀect of Re-PLPG-NLS on cells and cellular components was
studied in-depth.
Cellular localization
To investigate the biological behaviour of Re-PLPG-NLS in more
detail, its cellular localisation was assessed. The known lumi-
nescence1,59,79 of the Re-NH2 complex allowed us to visualize the
sub-cellular localization of its bioconjugates (Fig. 2). While the
Table 1 Cytotoxicities (IC50) of Re-NH2, Re-NLS, Re-PLPG-NLS, Re-Bombesin, Re-PLPG-Bombesin and cisplatin towards human cell lines
Compound HeLa darka (mM) HeLa UV (mM) MRC-5 darka (mM) MRC-5 UV (mM) PC-3 darka (mM) PC-3 UV (mM)
Re-NH2
1 187.1  17.9 17.3  2.9 >100 40.3  5.4 >100 >100
Re-NLS1 35.1  1.8 18.3  1.4 17.8  1.8 13.0  2.5 n.d. n.d.
Re-PLPG-NLS 14.5  5.2 9.3  0.8 36.2  0.6 20.5  5.5 n.d. n.d.
Re-Bombesin1 >100 5.3  1.0 44.1  9.9 41.6  15.9 >100 13.6  1.7
Re-PLPG-Bombesin >100 9.7  4.4 72.3  3.6 23.3  0.6 >100 19.2  2.4
Cisplatin 9.2  0.6 26.8  1.7 10.5  2.8 47.8  1.5 15.7  3.5 74.8  14.8
a IC50 aer 48 h treatment and incubation; n.d. ¼ not determined.
This journal is © The Royal Society of Chemistry 2014 Chem. Sci., 2014, 5, 4044–4056 | 4047
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complex by itself1 and its photo-caged version Re-PLPG were
observed exclusively in the cytoplasm (Fig. 2B and C), conju-
gation to an NLS peptide (Re-PLPG-NLS) brought the compound
inside the nucleus, as designed (Fig. 2D). However, the
compound did not show homogeneous distribution inside the
nucleus, but accumulated in a particular sub-nuclear domain –
the nucleolus. We previously reported this cellular distribution
for Re-NH2 directly conjugated to NLS peptide.1 Responsible
mainly for ribosomal RNA transcription, processing and
assembly, nucleoli also play an important role in cell cycle
regulation and stress response.80 As up-regulated ribosomal
RNA synthesis and the consequent enlargement of nucleoli are
characteristic of many cancer cells, these organelles have
gained attention as promising drug targets in the eld of anti-
cancer research.81
Quantication of Re-PLPG-NLS uptake in whole cells and
nucleoli
Due to possible quenching eﬀects inside the cells, uorescence
microscopy is not always reliable when it comes to quantifying
sub-cellular accumulation of a compound. Such eﬀects with
this class of compounds were recently observed by our
group.58,82 The cellular distribution of Re complexes can be
quantitatively determined by isolating the cellular compart-
ments of interest and measuring the Re content by ICP-MS.
According to this method, we incubated HeLa cells with 20 mM
of Re-NH2, Re-NLS and Re-PLPG-NLS for 2 h, and collected their
pellets (whole cell samples) or isolated their nucleoli through
diﬀerential centrifugation (nucleoli samples), following an
established method with opportune modications (Fig. S23 in
the ESI†).83 Both nucleoli and whole cell extracts were then
lysed, the protein content was measured, and the obtained
samples were lyophilized and analysed by ICP-MS. The Re
content of the whole cell samples followed the order of accu-
mulation Re-NH2 Re-NLS < Re-PLPG-NLS. Interestingly, these
data demonstrated very eﬃcient uptake of Re-PLPG-NLS by
HeLa. Indeed, in just 2 h, the cells internalised almost half of all
Re available in solution. Moreover, evaluation of the accumu-
lation of the target Re compound in the nucleoli indicated that
approximately 25% of Re-PLPG-NLS taken up by the cells was
concentrated in these organelles (Fig. S23†). The results
obtained from the quantitative determination are in good
agreement with the microscopic experiments and emphasize
the fast and signicant uptake of the Re complex.
Eﬀect of Re-PLPG-NLS on nucleic acids
In order to achieve a better understanding of the possible mode
of action of our Re compound, we investigated the possible
damage to DNA or RNA induced by Re-PLPG-NLS in the dark
and upon irradiation. Given the high positive charge of Re-
PLPG-NLS (5+) at physiological pH and the fact that the NLS
sequence is arginine- and lysine-rich, its DNA/RNA aggregating
behaviour could be hypothesized. Electrostatic forces indeed
play an important role in the interactions of small molecules
and proteins with nucleic acids, due to the polyanionic nature
of the latter. Arginine and lysine groups in peptides and
proteins are heavily involved in H-bonds in DNA/RNA–protein
complexes. Most of the small molecule compounds targeting
nucleic acids carry multiple positive charges as well.84,85 DNA
photo-cleavage experiments were performed on a closed
circular plasmid DNA (namely pcDNA3, see Fig. 3A). The DNA
was incubated with various concentrations of Re-PLPG-NLS,
and irradiated with UVA for 10 minutes. Re-PLPG-NLS cleaved
the plasmids upon light irradiation in a concentration-depen-
dent manner, converting the supercoiled DNA form (intact) to a
circular relaxed/nicked form (damaged). Linearization of
pcDNA3 was observed at a concentration as low as 10 mM, and
complete conversion of the supercoiled to the nicked congu-
ration occurred at a concentration of 50 mM (Fig. 3A). DNA
incubated with the rhenium bioconjugate in the dark did not
show a signicant eﬀect up to the highest concentration used in
this study (50 mM). It was also observed that the plasmid treated
with Re-PLPG-NLS displayed a smear band for high concentra-
tions of Re-PLPG-NLS in the dark. This eﬀect is due to NLS/DNA
interactions, which produced the deformed band, as conrmed
by DNA photo-cleavage experiments on NLS alone (see Fig. S24
in the ESI†).
As RNA is one of the major components of nucleoli, we
additionally investigated the eﬀect of Re-PLPG-NLS on a 638
nucleotide long RNA sequence (D135-L14 ribozyme derived
from the Sc.ai5g group II intron of S. cerevisiae).86 Denaturing
polyacrylamide gel electrophoresis (Fig. 3B) revealed a consid-
erable decrease in intensity and shi of the RNA band due to Re-
PLPG-NLS/RNA interactions and formation of non-migrating
RNA agglomerates (Fig. S26B†) at high concentrations of Re-
PLPG-NLS (100 mM). This eﬀect occurred both in the absence
and the presence of light, and no diﬀerence was observed for
UVA-irradiated samples. Re-NH2 or Re-PLPG alone did not
Fig. 2 Fluorescence microscopy of HeLa cells: (A) control; (B) Re-
NH2; (C) Re-PLPG and (D) Re-PLPG-NLS (50 mM, 2 h).
4048 | Chem. Sci., 2014, 5, 4044–4056 This journal is © The Royal Society of Chemistry 2014
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aﬀect the RNA (Fig. S27 and S28†). Given the localization of Re-
PLPG-NLS in RNA-rich nucleoli, it is possible that the strong
dark toxicity of this compound is linked to its eﬀect on RNA.
Morphological features induced by the targeted rhenium
complex
The deep cellular onset provoked by the target Re-PLPG-NLS is
not just related to an isolated biochemical pathway or biological
structure, but is also mirrored by macroscopic morphological
features. Major alterations can be conveniently monitored by
transmission electron microscopy (TEM), which is a particularly
powerful technique to distinguish sub-cellular compartments,
hence giving precious insights into the overall cell stress
response.87–90
Due to its traceability through confocal microscopy, its
valuable anti-proliferative eﬀects both in the dark and upon
irradiation, and its strong interaction with DNA and RNA, Re-
PLPG-NLS was chosen for this further biological characteriza-
tion. TEM images of irradiated and non-irradiated HeLa cells
incubated for 2 h with Re-PLPG-NLS were recorded. As shown in
Fig. 4, the resulting images (selection from a total pool of 40–60
images per sample, see Fig. S29 in the ESI† for other examples)
suggested that Re-PLPG-NLS induced the onset of severe
cellular stress, with features ascribable to late apoptosis and
necrosis. The sudden occurrence of membrane blebs, cyto-
plasm condensation, organelle packaging, extended vacuola-
tion and nuclear pyknosis indicated an initial triggering of
apoptosis. However, the extremely rapid uptake and activity of
Re-PLPG-NLS (conrmed by ICP-MS measurements, see
Fig. 3 (A) Electrophoretic resolution of pcDNA3 on 0.8% agarose gel-treated Re-PLPG-NLS at increasing concentration; (B) denaturing poly-
acrylamide gel electrophoresis of D135-L14 ribozyme sequence from Sc.ai5g intron of S. cerevisiae treated with Re-PLPG-NLS at increasing
concentration in the absence and presence of UVA irradiation.
Fig. 4 Transmission electron microscopy study of HeLa cell death morphology upon irradiation treatment at 350 nmwith 20 mM Re-PLPG-NLS
for 2 h; the features detected were organelle packaging, as well as cytoplasm condensation and pyknosis (yellow arrows), extensive vacuolation
(blue arrows), shrinkage and membrane blebbing (green arrows) and necrotic proﬁles (red arrows).
This journal is © The Royal Society of Chemistry 2014 Chem. Sci., 2014, 5, 4044–4056 | 4049
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“Quantication of Re-PLPG-NLS uptake in whole cells and
nucleoli” section) caused the balance to shi towards necrosis-
related eﬀects, such as loss of membrane integrity and nuclear
fragmentation (see Fig. 4).
Moreover, coherent with the insights obtained from the
cellular localization studies, major attention was paid to the
specic eﬀects triggered in nucleoli by Re-PLPG-NLS. Treatment
with the rhenium conjugate inuenced the nucleoli
morphology. In good agreement with established data, the
target sub-organelle presented a stress-altered morphology,
characterized by indicators such as the formation of nuclear
caps around the nucleolar body, separation of the brillar
centre from the granular centre, unravelling of the brillar
centre and migration of the whole nucleolar body to the
peripheral part of the nucleus (Fig. S30 in the ESI†).91,92 All these
features represent the main characteristics of nucleolar segre-
gation, which could contribute to the initial apoptotic event, as
well as to the overall cytotoxicity of Re-PLPG-NLS.
Mechanism of cell death induced by Re-PLPG-NLS
The mobilization of phosphatidylserine from the inner to the
outer layer of the cellular membrane promotes phagocytosis
and is considered a clear marker of an ongoing early apoptotic
event.93 Under severe stress, the loss of membrane integrity
enables a large pool of solutes to penetrate the plasma
membrane (which is normally impermeable to them), and
represents a signal of the occurrence of necrosis. The combi-
nation of two staining methods allows evaluation of the cell
death mechanism in large cell populations by ow cytometry,
using the Annexin V/propidium iodide (PI) assay. The rapid
triggering of cell death processes aer short incubation treat-
ment of HeLa cells with Re-PLPG-NLS investigated by TEM
showed a combination of apoptotic and necrotic stimuli.
Hence, it was of interest to study the contributions of these two
pathways to the cytotoxicity of Re-PLPG-NLS. In agreement with
the TEM data, Re-PLPG-NLS induced a drastic cellular eﬀect
aer only 2 h incubation with HeLa cells, with less than 10% of
cells still viable (see Fig. 5 and S31 in the ESI†). The majority of
the cell population displayed membrane symmetry due to
phosphatidylserine migration (Annexin V positive) and
membrane permeabilisation, which allowed PI internalization
(PI positive). The data support the thesis that Re-PLPG-NLS
induces severe cellular stress aer a short incubation time, to
which cells react by activating apoptosis. However, the very
dynamic onset of these events resulted in a pronounced late
apoptotic prole (see Fig. 5). These eﬀects could be observed for
both probes in the dark and upon irradiation, and were irre-
versible since the cells did not show any recovery over a time
frame of 24 h. Camptothecin was used as a positive control.
Conclusions
In this article, we described the eﬃcient caging of a Re(I) tri-
carbonyl N,N-bis(quinolinoyl) complex (Re-NH2) with a photo-
linker (PLPG) to give Re-PLPG. The latter was further conjugated
to two diﬀerent peptides for potential organelle/cellular uptake
(i.e. bombesin or NLS) to give Re-PLPG-NLS or Re-PLPG-
Bombesin. Photolysis experiments showed that complete
release of Re-NH2 could be achieved using a very low light dose
(1.2 J cm2). To the best of our knowledge, these are the rst two
examples of the selective release of an organometallic complex
from a bioconjugate using light activation. A rst biological
screening on diﬀerent cancer and non-tumorigenic cell lines
demonstrated the very valuable toxicity of the target complexes,
with IC50 values in the range of the established anti-cancer drug
cisplatin. It is noteworthy that, while Re-PLPG-Bombesin
showed a more marked 1O2-dependent cytotoxicity at low irra-
diation energy (2.58 J cm2), with a certain preference for cancer
cells over MRC-5, Re-PLPG-NLS showed a stronger (2-fold) anti-
proliferative eﬀect on malignant HeLa cells compared with Re-
NLS. In addition, Re-PLPG-NLS aﬀected non-cancerous MRC-5
cells less, compared with Re-NLS. Due to this interesting
behaviour, Re-PLPG-NLS was chosen for in-depth biological
characterization. Cellular biodistribution studies using ICP-MS
indicated an outstanding cellular uptake, close to 50% of all
available Re, with very rapid and strong accumulation in the
nucleoli. The penetration into sub-cellular compartments
(nucleus/nucleoli) allowed interaction between the Re complex
and nucleic acids. Re-PLPG-NLS was able to photo-cleave DNA
and created non-migrating RNA agglomerates. This molecular
dysfunction contributed to the induction of late apoptotic and
necrotic eﬀects, mirrored by morphological features such as
nucleolar segregation, pyknosis and extended vacuolation,
which resulted in cell death.
In conclusion, in this article, we present, for the rst time, a
strategy (organometallic complex – PLPG – targeting vector) to
selectively release an organometallic complex upon light irra-
diation. Current eﬀorts are aimed at increasing the ratio of dark
vs. UV light toxicity and producing this photo-cytotoxic action in
the PDT window.
Fig. 5 Induction of apoptosis/necrosis in HeLa cells treated with 20
mM Re-PLPG-NLS for 2 h in the dark and upon irradiation at 350 nm for
10 minutes at 0 h or 24 h recovery time; cmpt ¼ camptothecin (5 mM).
4050 | Chem. Sci., 2014, 5, 4044–4056 This journal is © The Royal Society of Chemistry 2014
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Experimental section
Materials
Chemicals and solvents were of reagent grade or better,
purchased from commercial suppliers and used without further
purication unless otherwise specied. The plasmid pcDNA3
was obtained from Invitrogen.
Instrumentation and methods
1H and 13C NMR measurements were carried out on Bruker 400
and 500 spectrometers and referenced to residual solvent peaks.
UV spectra were recorded on a Cary 50 Scan Varian spectropho-
tometer. ESI-MS, LC-MS and UPLC-MS were performed using a
Bruker Daltonics HCT 6000 mass spectrometer. LC-MS and
UPLC-MS spectra were recorded on a Waters Acquity™ system
equipped with a PDA detector and an auto-sampler. LC-MS was
carried out using an Agilent Zorbax 300 SB-C18 analytical
column (3.5 mmparticle size, 300 A˚ pore size, 150 4.6mm). The
LC run (ow rate: 0.5 mL min1) was performed with a linear
gradient of A (double distilled water containing 0.1% v/v formic
acid) and B (acetonitrile containing 0.1% v/v formic acid): t ¼
0 min, 5% B; t ¼ 3 min, 5% B; t ¼ 17 min, 100% B; t ¼ 20 min,
100%B; t¼25min, 5%B.UPLC-MSwasperformedonanAcquity
UPLC BEH C18 column (2.1  50 mm, 1.7 mm). The UPLC run
(ow rate: 0.6mLmin1) was carried out with a linear gradient of
A (double distilled water containing 0.1% v/v formic acid) and B
(acetonitrile containing 0.1% v/v formic acid): t¼ 0 min, 5% B; t
¼ 0.25min, 5%B; t¼ 1.5min, 100%B; t¼ 2.5min, 100%B.High
resolution ESI-MS spectra were recorded using a Bruker
ESQUIRE-LC quadrupole ion trap instrument. Preparative HPLC
purication was carried out on a Varian ProStar system and an
Agilent Zorbax 300 SB-C18 prep column (5 mmparticle size, 300 A˚
pore size, 150  21.1 mm. Flow rate: 20 mL min1). The runs
were performedwith a linear gradient of A (double distilledwater
containing 0.1%v/v triuoroacetic acid (TFA)) andB (acetonitrile
containing 0.1% v/v TFA, Sigma-Aldrich HPLC grade). Prepara-
tive runs: t¼ 0min, 5%B; t¼ 25min, 100%B; t¼ 30min, 100%B;
t ¼ 32 min, 5% B. Photolysis quantum yields were determined
using an Edinburgh LP-920 setup equipped with a Continuum
Surelite laser (355 nm). Cell culture irradiation was performed
using a Rayonet RPR-200 photochemical reactor with 6 bulbs (14
Weach) andmaximum intensity output at 350nm. Sampleswere
irradiated in a uorescence quartz cuvette (width 1 cm) placed in
the centre of the reactor. The light intensity at that spot,
measured with an X11 optometer (Gigahertz-Optik), was 42 W
m2. The temperature inside the reactor was 30 C.
Synthesis and characterization
Re-NH2. The complex was synthesised following a previously
published procedure. The analytical data were in agreement
with the literature report.59
PLPG. 1-5(1-(5-(N-maleimidomethyl)-2-nitrophenyl)ethanol
NHS ester). The photo-linker was synthesised following a
previously published procedure. The analytical data were in
agreement with the literature report.60
Re-PLPG. PLPG (30 mg, 0.072 mmol) and Re-NH2 (14.5 mg,
0.072 mmol) were dissolved in dry acetonitrile (1 mL). N,N-Dii-
sopropylethylamine (DIPEA) (23.5 mg, 31 mL, 0.18 mmol) was
then added to themixture, which was stirred for 2 h at 35 C. The
solvent was then removed under vacuum to give a sticky brown
solid, which was then puried by preparative HPLC to aﬀord Re-
PLPG as a light yellow solid. Yield: 58%. Characterisation data:
1H NMR (500 MHz, CDCl3) d 8.47 (dd,
3J ¼ 9.0, 5.5 Hz, 2H); 8.32
(dd, 3J¼ 16.5, 8.5 Hz, 2H); 7.89–7.81 (m, 5H); 7.71 (d, 3J¼ 8.0 Hz,
1H); 7.67–7.63 (m, 4H); 7.29 (dd, 3J ¼ 8.5, 1.5 Hz, 1H); 6.73 (s,
2H); 6.17 (q, 3J ¼ 6.5 Hz, 1H); 5.68 (m, 1H); 5.37 (d, 2J ¼ 18 Hz,
2H); 5.1 (dd, 2J ¼ 18, 7.25 Hz, 2H); 4.73 (d, 3J ¼ 6.0 Hz, 2H); 4.39
(s, broad, 1H); 3.85 (m, 2H); 3.24–3.21 (m, 2H); 2.07 (m, 2H); 1.64
(m, 2H); 1.57 (d, 3J ¼ 6.5 Hz, 3H). 13C NMR (500 MHz, CDCl3) d
22.3, 23.0, 27.2, 39.8, 40.9, 68.0, 68.5, 68.6 (2 peaks overlapping),
120.3, 125.2, 127.7, 128.4, 128.5, 128.6, 128.7, 133.2, 134.5, 139.9,
141.6, 141.7, 142.3, 146.8, 147.1, 156.1, 160.4, 160.7, 165.0, 170.3,
194.4, 195.9. ESI-MS m/z 943.2 [M]+. ESI HRMS calcd for
[C41H36N6O9Re]/z [M]
+ 943.20979, found 943.20958.
Peptide synthesis. The peptide synthesis was performed
using solid-phase techniques following a previously published
procedure.1
NLS (Cys-Arg-DArg-Arg-Lys(CONH2)). The peptide was syn-
thesised following a previously published procedure. The
analytical data were in agreement with the literature report.1
Bombesin (Cys-bAla-bAla-Gln-Trp-Ala-Val-Gly-His-Cha-Nle-
(CONH2)). The peptide was synthesised following a previously
published procedure. The analytical data were in agreement
with the literature report.1
Re-PLPG-NLS. Re-PLPG (86.0 mg, 0.0841 mmol) and the NLS
peptide (89.5 mg, 0.107 mmol) were pre-dissolved in DMSO (100
mL), and then in a 1 : 2 : 2 mixture of methanol–acetonitrile–
water (45 mL). The reaction mixture was stirred overnight at
room temperature. MeOH was removed using a rotary evapo-
rator, while water and acetonitrile were removed by lyophilisa-
tion. The compound was puried by preparative HPLC to aﬀord
a yellow-white solid. Characterisation data: ESI-MSm/z 830.3 [M
+ H]2+, 553.9 [M + 2H]3+, 415.7 [M + 3H]4+. ESI HRMS calcd for
[C68H92N22O14ReS]/z [M + H]
2+ 830.32599, found 830.32526,
calcd for [M + 2H]3+ 553.88660, found 553.88599, calcd for [M +
3H]4+ 415.66691, found 415.66631.
Re-PLPG-Bombesin. Re-PLPG (86.0 mg, 0.0841 mmol) and
bombesin peptide (89.5 mg, 0.107 mmol) were dissolved in a
1 : 1 mixture of acetonitrile–water (45 mL). The reactionmixture
was stirred overnight at room temperature. The solvent was
removed using a lyophiliser, and the crude compound was
puried by HPLC to aﬀord a yellow-white solid. Characterisation
data: ESI-MS m/z 1075.3 [M + H]2+, 717.4 [M + 2H]3+, 538.4 [M +
3H]4+. ESI HRMS calcd for [C68H92N22O14ReS]/z [M + H]
2+
1075.42557, found 1075.42494, calcd for [M + 2H]3+ 717.28632,
found 717.28571. Anal. found: C, 49.97; H, 4.90; N, 12.01. Calcd
for [C90H109F9N19O22ReS]: C, 49.69; H, 4.94; N, 12.38.
Determination of photo-uncaging quantum yields
20 mM DMSO stock solutions of the caged compounds were
diluted in phosphate buﬀer (pH ¼ 7.4) to achieve an optical
This journal is © The Royal Society of Chemistry 2014 Chem. Sci., 2014, 5, 4044–4056 | 4051
Edge Article Chemical Science
O
pe
n 
A
cc
es
s A
rti
cl
e.
 P
ub
lis
he
d 
on
 0
9 
Ju
ne
 2
01
4.
 D
ow
nl
oa
de
d 
on
 0
6/
11
/2
01
4 
14
:1
3:
12
. 
 
Th
is 
ar
tic
le
 is
 li
ce
ns
ed
 u
nd
er
 a
 C
re
at
iv
e 
Co
m
m
on
s A
ttr
ib
ut
io
n 
3.
0 
U
np
or
te
d 
Li
ce
nc
e.
View Article Online
density at 355 nm (OD(l ¼ 355 nm)) of approximately 0.2.
Aliquots of 100 mL were irradiated at 355 nm using an Edin-
burgh LP-920 setup equipped with a Continuum Surelite laser.
The laser was slightly misaligned to reach a suitable irradiation
power. Aer certain irradiation intervals (number of laser
shots), the solutions were transferred to amber HPLC vials with
200 mL inlets. 20 mL of the solutions were injected into an LC-MS
system. The percentage of remaining compound was plotted
against the number of laser shots and tted with a single
exponential decay curve:
C ¼ C0 exp(kx)
where C is the remaining concentration of the compound
(percentage relative to the initial concentration), C0 is the initial
concentration (percentage), k is the rate constant and x is the
irradiation dose.
The initial slope (less than 20% conversion) of the curve
(Scompound) was determined by taking the tangent to the rst
(<20% decomposition) points of the exponential t. It was then
used to calculate the photolysis quantum yield by comparing it
to the quantum yield of azobenzene photoisomerization. For
that purpose, trans-azobenzene was dissolved in methanol to
obtain an OD(l ¼ 355 nm) of approximately 0.2. It was then
irradiated under the same conditions as the compounds for the
measurements. UV/vis absorbance of the azobenzene solution
at 355 nm was then monitored. The remaining amount of trans-
azobenzene was then plotted against the number of laser shots,
and the initial slope of the curve (Sreference) was then obtained.
The photolysis quantum yields were then calculated using:
Fcompound ¼ Freference  Scompound
Sreference
 OD
355
reference
OD355compound
where Freference is the quantum yield of trans–cis isomerization
of azobenzene.68
Photolysis in UV reactor
20 mM DMSO stock solutions of the compounds to be irradi-
ated were diluted with 4 mL of PBS buﬀer (pH 7.4) to obtain
absorbance of 0.2 at 350 nm. The solutions were then irradiated
in uorescence quartz cuvettes (width 1 cm). At each irradiation
time, the solution compositions were analysed using LC-MS.
The relative concentrations of the photolysed compounds were
calculated from the areas of the corresponding LC-MS peaks.
Concentration % plotted as a function of photolysis time (or
irradiation dose) could be tted with a single exponential (rst
order kinetics law):
C ¼ C0 exp(kx)
where C0 is the initial concentration, k is the rate constant and x
is the irradiation dose.
Cell culture
Human cervical carcinoma cells (HeLa) were cultured in DMEM
(Gibco) with 5% fetal calf serum (FCS, Gibco), 100 U mL1
penicillin and 100 mg mL1 streptomycin at 37 C and 5% CO2.
Normal lung broblasts (MRC-5) were maintained in F-10
medium (Gibco) supplemented with 10% FCS (Gibco), 100 U
mL1 penicillin and 100 mg mL1 streptomycin at 37 C and 5%
CO2. Prostate carcinoma cells (PC-3) were cultured in Ham's F-
12K (Kaighn's) Medium (Gibco) supplemented with 10% FCS
(Gibco), 100 UmL1 penicillin and 100 mg mL1 streptomycin at
37 C and 5% CO2.
Cytotoxicity studies
The cytotoxicity of the rhenium complexes and their bio-
conjugates towards HeLa, MRC-5 and PC-3 cells in the presence
and absence of UV irradiation was measured using a uoro-
metric cell viability assay using resazurin (Promocell GmbH).
Cells were seeded in triplicate in 96-well plates at a density of 4
 103 cells per well in 100 mL medium 24 h prior to treatment.
To assess cytotoxicity, cells were treated with increasing
concentrations of the compounds for 48 h, whereas, to assess
phototoxicity, cells were treated with increasing concentrations
of the compounds for 4 h only. Aer that, the medium was
removed and replaced by fresh complete medium prior to 10
min UVA irradiation (2.58 J cm2). Cells were then returned to
the incubator for 48 h. Aer incubation, the medium was
replaced by 100 mL complete medium containing resazurin (0.2
mg mL1 nal concentration). Aer 4 h of incubation at 37 C
(overnight incubation for PC-3 due to slower metabolism of this
cell line), uorescence of the highly red uorescent resorun
product at 590 nm emission was quantied using a SpectraMax
M5 microplate reader with a 540 nm excitation wavelength.
In vitro uorescence evaluation
Cellular localization of the luminescent rhenium complexes
and bioconjugates was assessed using uorescence microscopy.
HeLa cells were grown in 2 mL medium on 18 mm Menzel-
glaser coverslips at a density of 1  105 cells per mL and incu-
bated with rhenium complexes at 50 mM for 2 h. Cells were xed
in 4% formaldehyde solution and mounted on slides for
viewing by confocal microscopy on a CLSM Leica SP5 micro-
scope. The rhenium complexes were excited at 405 nm, and
emission above 420 nm was recorded.
DNA photo-cleavage
The DNA photo-cleavage eﬀect provoked by complex Re-PLP-
NLS was investigated by electrophoresis. Supercoiled pcDNA3
plasmid (0.10 mg) was treated with increasing concentrations of
the rhenium compounds in buﬀer (50 mM Tris–HCl, 18 mM
NaCl, pH 7.2), incubated for 30 minutes at 25 C and irradiated
at 350 nm for 10 minutes (Rayomet Chamber Reactor, 2.58 J
cm2). A series of negative controls, in which the plasmid was
treated with NLS or Re-PLP-NLS in the dark at diﬀerent incu-
bation temperatures and in the presence of BstXI restriction
enzyme (to visualize the linearized form), were used for
comparative purposes (see Fig. S18†). Aer irradiation, sample
loading buﬀer (250 mg xylene cyanol in 33 mL of 150 mM Tris–
HCl buﬀer, pH 7.6, 0.1 M EDTA, 20% Ficoll 400 in 100 mL of
H2O) was added, and the probes were analyzed by
4052 | Chem. Sci., 2014, 5, 4044–4056 This journal is © The Royal Society of Chemistry 2014
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electrophoresis in 0.8% agarose in 1 TBE at 70 V (Biorad
Powerpack 1000, BioRad) for 2 h. The gel was pre-stained with
0.5 mg mL1 ethidium bromide, photographed and examined
using an AlphaDigiDoc 1000 CCD camera (Buchner Biotec AG)
and AlphaImager soware v1.3.0.7.
RNA
Preparation of RNA. The plasmid pT7D135-L14, encoding
the D135-L14 ribozyme sequence derived from the Sc.ai5g
intron from S. cerevisiae, was digested with HindIII and subse-
quently transcribed in vitro with home-made T7 RNA poly-
merase under standard conditions86 to give D135-L14 RNA.
D135-L14 was puried by denaturing polyacrylamide gel
electrophoresis.94
Gel electrophoresis studies. D135-L1486 RNA (1 mM) was
incubated with increasing concentrations of the rhenium
compounds in buﬀer (50 mM Tris–HCl, 18 mM NaCl, pH 7.2)
for 30 min at room temperature and irradiated at 350 nm for 5
min (Rayomet Chamber Reactor Complex, 1.29 J cm2). Control
experiments were carried out in the dark. An equal volume of
denaturing loading buﬀer (11.7 M urea, 40 mM Tris buﬀer, pH
7.5, 0.1% xylene cyanol, 0.1% bromophenol blue, 230 mM
sucrose, 0.8 mM EDTA, pH 8.0) was added to each sample, and
denaturing polyacrylamide gel electrophoresis was performed
using 5% acrylamide in TBE 1 buﬀer for 3 h at room
temperature. RNA bands were detected by UV shadowing.
Additionally, RNA bands were stained with ethidium bromide
and detected by UV excitation at 260 nm (Gel Visualization
System from Vilber).
Determination of the rhenium complex content in biological
samples
Sample preparation for ICP-MS
Whole cells. To perform ICP-MS measurements, HeLa cells
were seeded two days before treatment at a concentration of 4
105 cells per mL in a 75 cm2 cell culture ask until 80%
conuence, and incubated with the target complexes, namely
Re-NH2, Re-NLS or Re-PLPG-NLS, at 20 mM for 2 hours. The
medium was removed, and the cells were washed with PBS and
trypsinized. Aer re-suspension in PBS, the pellets were
collected by centrifugation at 5500 rpm for 4.5 minutes. The
pellets were re-dissolved in 500 mL of PBS, lysed by a freeze–thaw
cycle and treated in an ultrasonic bath (Digitana AG) for 20
minutes. The lysates were lyophilized using an Alpha 2-4 LD
plus (CHRIST).
Cell nucleoli. Nucleoli of HeLa cells were collected following
an established procedure with appropriate modications.81
Briey, HeLa cells were seeded two days before treatment at a
concentration of 4  105 cells per mL in a 75 cm2 cell culture
ask until 80% conuence. Cells were treated with 20 mM Re-
NH2, Re-NLS or Re-PLPG-NLS for 2 h, and the pellets were
collected and washed 3 times with ice cold PBS. The pellets were
incubated with lysis buﬀer (10 mM HEPES, 10 mM KCl, 1.5 mM
MgCl2, 0.5 mM dithiothreitol, pH 7.9) containing a protease
inhibitors cocktail (1/500 v/v, batch number: P8340, Sigma-
Aldrich) for 10 minutes, the membranes were disrupted and the
cells were homogenized in a 7 mL Dounce Homogenizator with
a tight pestle (type A, 20 strokes). The suspensions were
centrifuged at 250g at 4 C in a Centrifuge 5810R (Eppendorf) for
5 minutes, and the supernatant was removed. The pellets were
re-dissolved in 3 mL of a sucrose solution (0.25 M sucrose, 10
mM MgCl2) and layered with 3 mL of a second hypertonic
sucrose solution (0.35 M sucrose, 0.5 mM MgCl2). The suspen-
sions were centrifuged at 1450g at 4 C for 5 minutes. The
supernatant was discarded, and the pellets were re-suspended
in 3 mL of the second sucrose solution. The suspensions con-
taining the nuclear fraction were sonicated 5–6 times in 10 s
bursts (Bandelin Sonoplus GM70, 50% cycle, intervals of 10 s),
layered with a third hypertonic sucrose solution (0.88M sucrose,
0.5 mM MgCl2) and centrifuged at 3000g at 4 C for 10 minutes.
The pellets were re-suspended in the second sucrose solution
(0.35 M sucrose, 0.5 mMMgCl2), centrifuged at 1450g at 4 C for
5 minutes to obtain the pure nucleoli extracts (see Fig. S17†),
and stored at 80 C. All the steps of the isolation procedure
were monitored under a phase contrast microscope on Menzel-
gla¨ser coverslips (Olympus IX81). The collected nucleoli solu-
tions were lyophilized using an Alpha 2-4 LD plus (CHRIST).
ICP-MS measurements. To measure the Re content, the
biological samples were sent to Mikroanalytisches Labor
Pascher (Remangen, Germany). The samples were dissolved in a
PFA pressure system with nitric and hydrochloric acid at 180 C,
and Re187 (Ir193 as internal standard) was detected by ICP-MS
(Perkin Elmer Elan 5000).
Transmission electron microscopy
HeLa cells were seeded in 6-well plates containing carbon-
coated sapphire discs and glass cover slips at a concentration of
100 000 cells per mL and cultured at 37 C/5% CO2 for one day
(>80% conuence on the discs). The medium was then removed
and replaced with medium containing 20 mM Re-PLG-NLS. The
cells were further incubated for 2 hours and irradiated at 350
nm for 10 minutes (2.58 J cm2) or le non-irradiated (control).
Subsequently, the cells were processed by chemical xation and
high-pressure freezing, as follows.
Chemical xation (Fig. S23†). Cells were xed for 20 minutes
at room temperature with 2.5% glutaraldehyde and, subse-
quently, with 1%OsO4 for 1 hour, both in PBS (pH 7.3). The cells
were then incubated with 1% uranyl acetate in water for 1 hour,
dehydrated in an ethanol series and embedded into Epon/
Araldite.
High-pressure freezing (Fig. 4). Cells on sapphire discs (6
mm diameter) were frozen in an EM HPM100 high-pressure
freezing machine (Leica Microsystems, Vienna, Austria) using
the 6 mm cartridge system and a middle plate with ridge.
Subsequently, the samples were freeze-substituted in an EM
AFS2 unit (Leica) for 8 h at 90 C, 6 h at 60 C, 4 h at 30 C
and 1 h at 0 C, with periodic temperature transition gradients
of 30 C h1. Aerwards, the cells were incubated for 1 hour in
1% uranyl acetate in anhydrous acetone at 4 C prior to
embedding in Epon/Araldite.
Ultrathin 50 nm sections of all specimens were contrasted
with uranyl acetate and lead citrate, and analysed with a Tecnai
This journal is © The Royal Society of Chemistry 2014 Chem. Sci., 2014, 5, 4044–4056 | 4053
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G2 Spirit or CM 100 transmission electron microscope (FEI,
Eindhoven, The Netherlands) using an ORIUS 1000 CCD
camera (Gatan, Munich, Germany).
Annexin V/PI assay
The induction of apoptosis and necrosis in HeLa cells treated
with Re-PLPG-NLS was evaluated by means of the well-estab-
lished Annexin V/PI assay, using ow cytometry (BD Pharmin-
gen, Bioscience) according to the manufacturer’s instructions
with minor changes (BD Pharmingen, Mat. no. 556419). Briey,
cells were seeded in a Petri dish at a concentration of 2  105
cells mL1 and cultured at 37 C/6% CO2 for 24 h. The medium
was replaced with fresh medium containing 20 mM Re-PLPG-
NLS. The cells were incubated for 2 h, and then themediumwas
replaced with fresh medium and the Petri dish was irradiated at
350 nm for 10 minutes (2.58 J cm2). To observe the direct
eﬀects aer irradiation, the cells were immediately collected for
FACS analysis, whereas, for the recovery experiments, the
medium was replaced and the cells were further incubated for
24 h at 37 C/6% CO2. The cells were then trypsinized and
pelleted, washed twice with ice cold PBS, centrifuged at 250g for
5 minutes and re-suspended in binding buﬀer (10 mM HEPES,
140mMNaCl, and 2.5 mMCaCl2, pH 7.4) at a concentration of 1
 106 cells per mL. 100 mL of the obtained suspension was
transferred into an FACS culture tube (1 105 cells), and 5 mL of
FITC Annexin V complex solution and 5 mL of a 50 mg mL1
propidium iodide (PI) solution were added. Samples were
incubated for 15 minutes at room temperature (25 C) in the
dark, 400 mL of binding buﬀer was added, and the probes were
analyzed using a CynAn ADP9 ow cytometer with the FITC (for
Annexin V-FITC, excitation ¼ 488 nm, emission ¼ 515–545 nm)
and PE-Texas Red channels (for PI, excitation ¼ 488 nm,
emission¼ 564–606 nm). The data were analyzed using Summit
v4.3 soware. Camptothecin, used at 5 mM for 2 or 24 h, and
untreated cells in the dark or under irradiation were used as
positive controls.
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